Controlled Release, Intestinal Transport, and Oral Bioavailablity of Paclitaxel Can be Considerably Increased Using Suitably Tailored Pegylated Poly(Anhydride) Nanoparticles

Journal of Pharmaceutical Sciences

Volumn 104, Issue 9, 2015, Pages 2877-2886

  Calleja, Patricia ^a   Espuelas, Socorro ^a   Vauthier, Christine ^b,c   Ponchel, Gilles ^b,c   Irache, Juan M ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIV PARIS SUD   (France)

^c CNRS   (France)

Author keywords

bioavailability; controlled release; cyclodextrins; nanoparticles; paclitaxel; pegylation; permeability; transmucosal delivery

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN; CYCLODEXTRIN; MACROGOL 2000; NANOPARTICLE; PACLITAXEL; PEGYLATED POLY(ANHYDRIDE) NANOPARTICLE; UNCLASSIFIED DRUG; ACID ANHYDRIDE; ANTINEOPLASTIC AGENT; DELAYED RELEASE FORMULATION; DRUG CARRIER; MACROGOL DERIVATIVE;

ANIMAL EXPERIMENT; APPARENT PERMEABILITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CRYOELECTRON MICROSCOPY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG PENETRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDRODYNAMICS; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; LIMIT OF QUANTITATION; LIQUID LIQUID EXTRACTION; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; QUALITY CONTROL; SCANNING ELECTRON MICROSCOPY; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; C57BL MOUSE; CHEMISTRY; DELAYED RELEASE FORMULATION; MEDICINAL CHEMISTRY; SOLUBILITY; TRANSPORT AT THE CELLULAR LEVEL;

ANHYDRIDES; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CHEMISTRY, PHARMACEUTICAL; CYCLODEXTRINS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; INTESTINAL ABSORPTION; MICE; MICE, INBRED C57BL; NANOPARTICLES; PACLITAXEL; POLYETHYLENE GLYCOLS; SOLUBILITY;

EID: 84939256523     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24354     Document Type: Article

References (40)

1. Borner M, Scheithauer W, Twelves C, Maroun J, Wilke H,. 2001. Answering patients' needs: Oral alternatives to intravenous therapy. Oncologist 6: 12-16.
2. O'Neill VJ, Twelves CJ,. 2002. Oral cancer treatment: Developments in chemotherapy and beyond. Br J Cancer 87: 933-937.
3. Batlle J, Arranz E, de Castro Carpeño J, Sáez E, Auñõn P, Sánchez A, Barõn M,. 2004. Oral chemotherapy: Potential benefits and limitations. Clin Transl Oncol 6: 335-340.
4. Halfdanarson TR, Jatoi A,. 2010. Oral cancer chemotherapy: The critical interplay between patient education and patient safety. Curr Oncol Rep 12: 247-252.
5. Weingart SN, Brown E, Bach PB, Eng K, Johnson SA, Kuzel TM, Langbaum TS, Leedy RD, Muller RJ, Newcomer LN, O'Brien S, Reinke D, Rubino M, Saltz L, Walters RS,. 2008. NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw 6: S1-14.
6. Rowinsky EK, Donehower RC,. 1995. Drug-therapy-Paclitaxel (taxol). New Engl J Med 332: 1004-1014.
7. Kingston DGI,. 2009. Tubulin-interactive natural products as anticancer agents. J Nat Prod 72 (2009): 507-515.
8. Holton RA, Kim HB, Somoza C, Liang F, Biediger RJ, Boatman PD, Shindo M, Smith CC, Kim SC, Nadizadeh H, Suzuki Y, Tao CL, Vu P, Tang SH, Zhang PS, Murthi KK, Gentile LN, Liu JH,. 1994. First total synthesis of taxol. 2. Completion of the c-ring and d-ring. J Am Chem Soc 116: 1599-1600.
9. Poupat C, Hook I, Gueritte F, Ahond A, Guenard D, Adeline MT, Wang XP, Dempsey D, Breuillet S, Potier P,. 2000. Neutral and basic taxoid contents in the needles of Taxus species. Planta Med 66: 580-584.
10. Merckle L, Dubois J, Place E, Thoret S, Gueritte F, Guenard D, Poupat C, Ahond A, Potier P,. 2001. Semisynthesis of D-ring modified taxoids: Novel thia derivatives of docetaxel. J Org Chem 66: 5058-5065.
11. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH,. 1996. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56: 2112-2115.
12. Peltier S, Oger JM, Lagarce F, Couet W, Benoit JP,. 2006. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm Res 23: 1243-1250.
13. Mazzaferro S, Bouchemal K, Ponchel G,. 2012. Oral delivery of anticancer drugs I: General considerations. Drug Discov Today 18: 25-34.
14. Davis ME, Chen Z, Shin DM,. 2008. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat Rev Drug Discov 7: 771-782.
15. Brooks T, Minderman H, O'Loughlin KL, Pera P, Ojima I, Baer MR, Bernacki RJ,. 2003. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther 2: 1195-1205.
16. van Asperen J, Van Tellingen O, van der Valk MA, Rozenhart M, Beijnen JH,. 1998. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin Cancer Res 4: 2293-2297.
17. Woo JS, Lee CH, Shim CK, Hwang SJ,. 2003. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharmac Res 20: 24-30.
18. Lee E, Lee J, Lee IH, Yu M, Kim H, Chae SY, Jon S,. 2008. Conjugated chitosan as a novel platform for oral delivery of paclitaxel. J Med Chem 51: 6442-6449.
19. Gao P, Rush BD, Pfund WP, Huang TH, Bauer JM, Morozowich W, Kuo MS, Hageman MJ,. 2003. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J Pharm Sci 92: 2386-2398.
20. Khandavilli S, Panchagnula R,. 2007. Nanoemulsions as versatile formulations for paclitaxel delivery: Peroral and dermal delivery studies in rats. J Invest Dermatol 127: 154-162.
21. Mo R, Jin X, Li N, Ju C, Sun M, Zhang C, Ping Q,. 2011. The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles. Biomaterials 32: 4609-4620.
22. Yoncheva K, Calleja P, Agüeros M, Petrov P, Miladinova I, Tsvetanov C, Irache JM,. 2012. Stabilized micelles as delivery vehicles for paclitaxel. Int J Pharm 436: 258-264.
23. Agueros M, Zabaleta V, Espuelas S, Campanero MA, Irache JM,. 2010. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles. J Control Release 145: 2-8.
24. Fonseca C, Simoes S, Gaspar R,. 2002. Paclitaxel-loaded PLGA nanoparticles: Preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 83: 273-286.
25. Roger E, Lagarce F, Garcion E, Benoit JP,. 2009. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J Control Release 140: 174-181.
26. Agueros M, Espuelas S, Esparza I, Calleja P, Penuelas I, Ponchel G, Irache JM,. 2011. Cyclodextrin-poly(anhydride) nanoparticles as new vehicles for oral drug delivery. Expert Opin Drug Deliv 8: 721-734.
27. Agueros M, Ruiz-Gaton L, Vauthier C, Bouchemal K, Espuelas S, Ponchel G, Irache JM,. 2009. Combined hydroxypropyl-beta-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel. Eur J Pharm Sci 38: 405-413.
28. Arbos P, Campanero MA, Arangoa MA, Renedo MJ, Irache JM,. 2003. Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties. J Control Release 89: 19-30.
29. Fenyvesi F, Fenyvesi E, Szente L, Goda K, Bacso Z, Bacskay I, Varadi J, Kiss T, Molnar E, Janaky T, Szabo G, Vecsernyes M,. 2008. P-glycoprotein inhibition by membrane cholesterol modulation. Eur J Pharm Sci 34: 236-242.
30. Ishikawa M, Yoshi H, Furuta T,. 2005. Interaction of modified cyclodextrins with cytochrome P-450. Biosci Biotechnol Biochem 69: 246-248.
31. Zabaleta V, Ponchel G, Salman H, Agueros M, Vauthier C, Irache JM,. 2012. Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: Permeability and pharmacokinetic study. Eur J Pharm Biopharm 81: 514-523.
32. Wang SW, Monagle J, McNulty C, Putnam D, Chen HM,. 2004. Determination of P-glycoprotein inhibition by excipients and their combinations using an integrated high-throughput process. J Pharm Sci 93: 2755-2767.
33. Bravo-Osuna I, Vauthier C, Chacun H, Ponchel G,. 2008. Specific permeability modulation of intestinal paracellular pathway by chitosan-poly (isobutylcyanoacrylate) core-shell nanoparticles. Eur J Pharm Biopharm 69: 436-444.
34. Lionetto MG, Giordano ME, De Nuccio F, Nicolardi G, Hoffmann EK, Schettino T,. 2005. Hypotonicity induced K+ and anion conductive pathways activation in eel intestinal epithelium. J Exp Biol 208: 749-760.
35. Cai QX, Zhu KJ, Chen D, Gao LP,. 2003. Synthesis, characterization and in vitro release of 5-aminosalicylic acid and 5-acetyl aminosalicylic acid of polyanhydride-P(CBFAS). Eur J Pharm Biopharm 55: 203-208.
36. Yu Y, Lu T, Zhao W, Sun W, Chen T,. 2011. Preparation and characterization of BSA-loaded microspheres based on polyanhydrides. J Appl Polym Sci 121: 352-358.
37. Varma MVS, Panchagnula R,. 2005. Enhanced oral paclitaxel absorption with vitamin E-TPGS: Effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci 25: 445-453.
38. Varma MVS, Panchagnula R,. 2005. Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability. J Pharm Sci 94: 1694-1704.
39. Yang SC, Gursoy RN, Lambert G, Benita S,. 2004. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm Res 21: 261-270.
40. Faulkner TP, Cantleberry SB, Watts VJ, Hussain AS,. 1990. Comparative pharmacokinetics of ethanol in inbred strains of mice using doses based on total-body water. Alcohol Clin Exp Res 14: 82-86.